MetLife Investment Management LLC Acquires 972,699 Shares of ADMA Biologics Inc $ADMA

Key Points

• MetLife Investment Management LLC increased its stake in ADMA Biologics Inc by 714.1%, acquiring a total of 972,699 shares to own about 0.47% of the company, valued at $22 million.
• Several other institutional investors, including Skandinaviska Enskilda Banken AB and SVB Wealth LLC, have recently taken new positions in ADMA Biologics, contributing to 75.68% of the stock ownership being held by institutional investors.
• ADMA Biologics recently reported a quarterly EPS of $0.15, which exceeded analysts’ estimates, while its revenue grew by 13.8% year-over-year, indicating strong business performance.

MetLife Investment Management LLC boosted its holdings in shares of ADMA Biologics Inc (NASDAQ:ADMA - Free Report) by 714.1% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,108,911 shares of the biotechnology company's stock after acquiring an additional 972,699 shares during the period. MetLife Investment Management LLC owned about 0.47% of ADMA Biologics worth $22,001,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Skandinaviska Enskilda Banken AB publ bought a new position in ADMA Biologics during the 1st quarter worth about $35,000. SVB Wealth LLC bought a new position in ADMA Biologics during the 1st quarter worth about $35,000. Smartleaf Asset Management LLC grew its holdings in ADMA Biologics by 161.4% during the 1st quarter. Smartleaf Asset Management LLC now owns 2,418 shares of the biotechnology company's stock worth $49,000 after acquiring an additional 1,493 shares in the last quarter. Tsfg LLC bought a new position in ADMA Biologics during the 1st quarter worth about $51,000. Finally, Brooklyn Investment Group grew its holdings in ADMA Biologics by 28,655.6% during the 1st quarter. Brooklyn Investment Group now owns 2,588 shares of the biotechnology company's stock worth $51,000 after acquiring an additional 2,579 shares in the last quarter. 75.68% of the stock is currently owned by institutional investors.

Insider Activity at ADMA Biologics

In related news, Director Lawrence P. Guiheen sold 20,000 shares of the stock in a transaction that occurred on Monday, June 9th. The shares were sold at an average price of $20.96, for a total value of $419,200.00. Following the completion of the transaction, the director directly owned 94,830 shares of the company's stock, valued at $1,987,636.80. This trade represents a 17.42% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Jerrold B. Grossman sold 10,000 shares of the stock in a transaction that occurred on Monday, June 9th. The shares were sold at an average price of $21.31, for a total transaction of $213,100.00. Following the completion of the transaction, the director directly owned 478,194 shares of the company's stock, valued at $10,190,314.14. The trade was a 2.05% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 455,621 shares of company stock valued at $9,461,633 in the last three months. 3.50% of the stock is owned by insiders.

ADMA Biologics Stock Performance

Shares of ADMA Biologics stock opened at $17.80 on Monday. The firm has a market capitalization of $4.25 billion, a P/E ratio of 20.70 and a beta of 0.38. The company has a quick ratio of 2.78, a current ratio of 5.33 and a debt-to-equity ratio of 0.21. The company has a 50 day moving average price of $17.91 and a 200 day moving average price of $18.90. ADMA Biologics Inc has a 52 week low of $13.50 and a 52 week high of $25.67.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The biotechnology company reported $0.15 EPS for the quarter, beating the consensus estimate of $0.14 by $0.01. The firm had revenue of $121.98 million during the quarter, compared to analyst estimates of $121.77 million. ADMA Biologics had a net margin of 44.06% and a return on equity of 41.01%. ADMA Biologics's revenue was up 13.8% on a year-over-year basis. During the same period last year, the firm posted $0.13 EPS. Sell-side analysts expect that ADMA Biologics Inc will post 0.51 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have issued reports on the stock. Raymond James Financial increased their target price on shares of ADMA Biologics from $25.00 to $32.00 and gave the stock a "strong-buy" rating in a report on Thursday, May 8th. Wall Street Zen lowered shares of ADMA Biologics from a "hold" rating to a "sell" rating in a research report on Friday, May 9th. One equities research analyst has rated the stock with a Strong Buy rating and two have given a Buy rating to the company's stock. Based on data from MarketBeat.com, ADMA Biologics has an average rating of "Buy" and a consensus target price of $27.67.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.

Want to see what other hedge funds are holding ADMA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ADMA Biologics Inc (NASDAQ:ADMA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.